



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	Group Art Unit: 1615
Mathias Bergman et al.)	Examiner: Unassigned
Application No.: 10/530,024)	Confirmation No.: 2906
Filing Date: April 3, 2005)	
Title: TUMOR TARGETING AGENTS AND)	
USES THEREOF)	

**SECOND
INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a SECOND Information Disclosure Statement (IDS) and accompanying form PTO-1449 for the above-identified patent application.


- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of 180 as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ Charge _____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of _____ is enclosed for the fee due.
- ☐ Charge _____ to credit card for the fee due. Form PTO-2038 is attached.
- ☒ The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL AND ROONEY PC

Date September 14, 2006

By:


Susan M. Dadiq
Registration No. 40373

P.O. Box 1404
Alexandria, VA 22313-1404
1737 King Street, Suite 500
Alexandria, VA 22314-2727
703 836 6620



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Mathias Bergman et al.) Group Art Unit: 1615
Application No.: 10/530,024) Examiner:
Filed: April 3, 2005) Confirmation No.: 2906
For: TUMOR TARGETING AGENTS AND)
USES THEREOF)
)
)
)
)

SECOND INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98. Also enclosed is a copy of a European Office Action issued in the correspondence European Application. Applicants note that all of the references cited in this European Office Action have previously been submitted in an Information Disclosure Statement filed on April 1, 2005 in the present application with the exception of the article by ARAP et al. Therefore, pursuant to 37 C.F.R. § 1.98, a copy of the ARAP et al. article is enclosed.

Non-Patent Literature Documents

1. ARAP et al., "Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model," *Science*, 1998, vol. 279, pp. 377-380, American Association for the Advancement of Science, Washington, D.C.

The document is being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since this document is being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.


To assist the Examiner, the document is listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date: September 14, 2006

By:


Susan M. Dadio
Registration No. 40373

P.O. Box 1404
Alexandria, VA 22313-1404
703 836 6620

SEP 14 2006

Complete if Known

SECOND
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/530,024
Filing Date	April 3, 2005
First Named Inventor	Mathias Bergman et al.
Examiner Name	Unassigned
Attorney Docket No.	1014975-000113

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS						
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	ARAP et al., "Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model," <i>Science</i> , 1998, vol. 279, pp. 377-380, National Association for the Advancement of Science, Washington, D.C.

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.